Iyer Ramji, Chalekian Aaron, Lane Randy, Evans Mike, Yi Seung, Morris John
LivaNova PLC, Maple Grove, MN, USA.
Neovasc Inc., Richmond, BC, Canada.
Cardiovasc Eng Technol. 2018 Sep;9(3):301-338. doi: 10.1007/s13239-018-0364-z. Epub 2018 Jun 27.
Transcatheter Mitral Valve Replacement (TMVR) is currently under clinical investigation as a viable treatment option for mitral regurgitation (MR). Therefore, it is important to outline the key functional requirements of a TMVR prosthesis in order to provide an overall approach to assessing mitral valve replacement devices utilizing a combination of in vitro and preclinical methods. This article provides a review of the mitral valve disease as well as general considerations and guidance for developing a TMVR device based on International Industry Standards. Specific details pertaining to the mitral valve apparatus, morphology of mitral valve disease, assessment of specific patient population as well as hazard analysis to evaluate and develop a TMVR device to treat a specific patient population have been included. The details contained within this report are not all inclusive or explicate for every technology being developed but rather thought of as a general guide on how a TMVR technology could be developed in alignment with International Industry Standards. Key learnings from the Transcatheter Aortic Valve Replacement (TAVR) experience has also been considered and taken into account when outlining this general guidance for TMVR. Key learning points from the TAVR development experience included the following: quantification of acceptable levels of paravalvular leak, valve migration potential using various anchoring methods and overall implant frame failure modes when treating the native aortic valve. It should be noted that TAVR is over a decade further along in development and clinical experience compared to TMVR. These key learnings from the early experience with TAVR should be considered with all transcatheter development projects.
经导管二尖瓣置换术(TMVR)目前正在进行临床研究,作为二尖瓣反流(MR)的一种可行治疗选择。因此,概述TMVR假体的关键功能要求非常重要,以便提供一种利用体外和临床前方法相结合来评估二尖瓣置换装置的整体方法。本文综述了二尖瓣疾病,以及基于国际行业标准开发TMVR装置的一般考虑因素和指导原则。其中包括与二尖瓣装置相关的具体细节、二尖瓣疾病的形态学、特定患者群体的评估,以及用于评估和开发治疗特定患者群体的TMVR装置的危害分析。本报告中包含的细节并非涵盖所有正在开发的技术,也并非对每种技术都进行详细阐述,而是被视为关于如何按照国际行业标准开发TMVR技术的一般指南。在为TMVR制定此一般指南时,还考虑并纳入了经导管主动脉瓣置换术(TAVR)经验中的关键经验教训。TAVR开发经验中的关键要点包括以下内容:瓣周漏可接受水平的量化、使用各种锚定方法时瓣膜迁移的可能性,以及治疗天然主动脉瓣时整体植入框架的失效模式。需要注意的是,与TMVR相比,TAVR的开发和临床经验要早十多年。所有经导管开发项目都应考虑TAVR早期经验中的这些关键经验教训。